Orserdu's Real-World Impact on Breast Cancer Treatment
Recent findings presented at the 2024 San Antonio Breast Cancer Symposium have shed light on the effectiveness of Orserdu (elacestrant) in treating HR-positive/HER2-negative advanced breast cancer with ESR1 mutations. In a real-world setting, Orserdu has shown comparable or slightly better time to treatment discontinuation and time to next treatment than previously reported in the phase 3 EMERALD trial.
Understanding the Data
- Progression-free survival: The duration during which a patient’s disease does not worsen.
- Real-world time to next treatment: The period from starting treatment to initiating the next therapy.
- Real-world time to treatment discontinuation: The time from starting treatment to stopping it for any reason.
These metrics underscore the potential of Orserdu to significantly impact patient care and outcomes.
The Importance of Access
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine at Beth Israel Deaconess Medical Center in Boston, highlighted the importance of improving patient access to innovative therapies like Orserdu. He emphasized the need for not only the medication but also the companion diagnostic treatments required to adopt these therapies effectively. This is particularly crucial in community or rural settings, which may lack the infrastructure or resources of larger academic centers.
Advocacy for Coverage
Dr. Lloyd also stressed the importance of advocacy by oncologists, industry partners, and advocacy networks to ensure these treatments are covered by insurance companies. Ensuring adequate access to these therapies is essential for helping patients live longer, better lives with control of their breast cancer.
Conclusion
The data presented at the symposium and the insights from Dr. Lloyd highlight the ongoing need for advancements in breast cancer treatment and the critical importance of making these innovative therapies accessible to all patients, regardless of their geographic location or economic status.
